Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

Affiliations

• ¹ MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.
• ² Institut Gustave Roussy, Villejuif, France.
• ³ Division of Hematology, School of Medicine, University of Colorado, Aurora, Colorado, USA.
• ⁴ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ⁵ Northwestern University, Chicago, Illinois, USA.
• ⁶ Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• ⁷ Servier BioInnovation LLC, Boston, Massachusetts, USA.
• ⁸ Agios Pharmaceuticals, Inc, Cambridge, Massachusetts, USA.
• ⁹ Memorial Sloan Kettering Cancer Center, New York City, New York, USA.